Medeon Biodesign, Inc. (6499.TWO)

TWD 39.6

(-1.0%)

Market Cap (In TWD)

3.64 Billion

Revenue (In TWD)

196.26 Million

Net Income (In TWD)

-1.2 Billion

Avg. Volume

96.06 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
39.1-54.9
PE
-
EPS
-
Beta Value
0.704
ISIN
TW0006499007
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Dr. Yue-Teh Jang Ph.D.
Employee Count
-
Website
https://www.medeonbio.com
Ipo Date
2014-12-11
Details
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States. The company focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. It is involved in medical device contract manufacturing, equity investment and commerce of medical devices, manufacturing and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is headquartered in Taipei, Taiwan.